Health Robotics Expands into Qatar with i.v.STATION Robot Pediatric Installation at Hamad's Al-Wakra Hospital

News provided by

Health Robotics

07 Feb, 2013, 13:00 GMT

BOZEN, SUD-TIROL, Italy, February 7, 2013 /PRNewswire/ --

Health Robotics reported today its first positive results originating from its 2012 change in distribution channels within the Gulf Cooperation Council (GCC) area, and the exclusive appointment of PharmaTech as the replacement of AHCSC. Health Robotics is pleased to extend its unique technology to the first GCC hospital to utilize i.v.STATION (or any other IV robotic technology) for pediatric patients.

Fathia Adheir, Director of Pharmacy at Hamad's Al-Wakra Hospital stated: "We selected the i.v.STATION Robot over other available IV Robots based on its cost-effectiveness, efficient use of space, and reduction of IV medication errors. I'm quite satisfied with the service provided by Health Robotics' and PharmaTech's engineering teams, and their excellent support for our needs as a mission-critical and pediatric healthcare facility. Al-Wakra Hospital is supported by the first digital pharmacy in Qatar, with the latest technology available in the Middle East. Al-Wakra Hospital is the 8th hospital of Hamad Medical Corporation; the 210-bed facility has a flexible capacity for an additional 50 beds, as well as 96 critical care beds, serving the communities of Al-Wakra and Doha International Airport as well as the population living in the south of the country up to the border with KSA."

Health Robotics' i.v.STATION pediatric utilization was already proven successfully in the USA and Europe, with Children's Hospital of Los Angeles, Duke University Children's Hospital and Health Center in Durham, Miller Children's Hospital in Long Beach, Sophia Children's Hospital at Erasmus University Medical Center in Rotterdam, and Milan's Mangiagalli Neonatology and Neonatal Intensive Care Unit.

Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "It is indeed a privilege for Health Robotics to be selected in a competitive tender award by Hamad Medical Corporation in order to serve the pediatric patient needs of the Qatari Government. I personally look forward to visit Hamad Medical Center and study the expansion of Health Robotics' technology and IV workflow solutions into the rest of the healthcare facilities of Hamad Medical Corporation."

About Health Robotics:

Founded in 2006 and now reaching over 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 350 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies[1],[2]] to greatly contribute to ease hospitals' growing pressures to improve patient safety[1], increase throughput, and contain costs[1]. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug[1] and diluent[1] exchange errors, improve drug potency[2], decrease other medical mistakes and sterility risks, work more efficiently[1], reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com

--------------------------------------------------

1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

For additional information, please contact:

Eman Hashim
eman@pharmauae.com
Phone: +971-506-609-957

Claudia Perez
perez@health-robotics.com
Phone +1-786-417-1251